Loading
Opus Genetics, Inc. Stock: price and insider trades · United States
US·Mcap US$319.5M
No insider purchase over the last 90 days. The latest was filed 31 Dec 2025.
Opus Genetics, Inc.: what insiders have been doing
Opus Genetics, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 18 October 2025 and 18 October 2026, 18 insiders published 47 filings.
The record shows 1 purchase on the open market worth €136k, made by 1 insider, against 15 sales worth €10.3M by 7 insiders. Netting one side against the other leaves €10.2M of net selling. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 senior executive. The largest single trade was a sale of €7.4M by Foundation Fighting Blindness Retinal Degeneration Fund, published on 11 December 2025.
The last insider purchase was made public on 31 December 2025, 291 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
With 47 filings in twelve months, the company is more active than the median of 22 filings across the 5,458 companies we follow on the same exchange. Looking back to 2021, when coverage begins, insiders filed 15 purchases and 15 sales. The 10-K for the year ended 31 December 2025 shows 14.2 m USD of revenue and -49.6 m USD of net income.
Other companies in the same market with recent insider buying flagged by our signals: GameStop Corp. and Heico Corp. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
146
Thresholds
n/a
Buy Volume
€602,162
15 ops. · all time
Sell Volume
€10M
15 ops. · all time
Who traded when
BuySaleGeorge Magrath2 buys3 sales
Robert E. Gagnon3 sales
Ashwath Jayagopal2 sales
Foundation Fighting Blindness Retinal Degeneration Fund2 sales
Rabourn Amy Zaremba2 sales
Schachle Joseph K2 sales
+2 other insiders
Since the insiders bought
- +121.2%Entry US$2.12 · Close at T+90 US$4.69
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Opus Genetics, Inc. Strong Buy (bullish), based on 17 analysts. Average price target: US$13.47.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.84
Analyst consensus
17 analystsStrong buy
US$8.00Target US$13.47(+251%)US$20.00
Income statement
RevenueUS$14.2M
EBITDA-US$48.1M-339% margin
Net income-US$49.6M-349.3% margin
Valuation
PER (forward)-5.4x
Beta0.62
Balance sheet & cash
Market capUS$319.5M
Total debtUS$1.1M
Free Cash Flow-US$35.3M
Profitability & ownership
ROE-4796.5%
ROA-48.1%
% insiders12.2%
% institutions69.3%
Last declaration on 2 October 2026
Declarations146 total
556,000 shares@ US$4.956824.7% of flowCommon StockSEC:0002042266-26-000002:0
392,157 shares@ US$1.150.027% mcap30.8% of flowCommon StockSEC:0001140361-26-036347:0
75,541 shares@ US$5.970.027% mcap30.8% of flowCommon StockSEC:0001140361-26-036347:1
28,000 shares@ US$4.54330.0076% mcap37.5% of flowCommon StockSEC:0001140361-26-035912:0
784,314 shares@ US$1.150.054% mcap43.8% of flowCommon StockSEC:0001140361-26-035913:0
28,000 shares@ US$4.450.0075% mcap36.7% of flowCommonSEC144:0001974158-26-000100
7,783 shares@ US$2.94770.0014% mcap6.9% of flowCommon StockSEC:0000905148-26-003351:0
9,475 shares@ US$2.94730.0017% mcap1.9% of flowCommon StockSEC:0000905148-26-003352:0
7,783 shares@ US$3.050.0014% mcap7.1% of flowCommonSEC144:0001974158-26-000091
9,475 shares@ US$3.050.0018% mcap2.0% of flowCommonSEC144:0001974158-26-000090
7,429 shares@ US$2.970.0013% mcap18.9% of flowCommonSEC144:0001974078-26-000273
4,644 shares@ US$2.940.0008% mcap23.9% of flowCommonSEC144:0001974078-26-000274
7,470 shares@ US$5.23710.0021% mcap32.8% of flowCommon StockSEC:0000905148-26-001867:0
7,842 shares@ US$5.18460.0022% mcap11.9% of flowCommon StockSEC:0000905148-26-001862:0
7,542 shares@ US$5.19170.0021% mcap47.1% of flowCommon StockSEC:0000905148-26-001863:0
9,511 shares@ US$5.220.0027% mcap3.4% of flowCommon StockSEC:0000905148-26-001864:0
1,641 shares@ US$5.2040.0005% mcap17.4% of flowCommon StockSEC:0000905148-26-001865:0
4,697 shares@ US$5.22020.0013% mcap42.0% of flowCommon StockSEC:0000905148-26-001866:0
24,367 shares0Common StockSEC:0000905148-26-001786:0
24,367 shares0Common StockSEC:0000905148-26-001787:0
24,367 shares0Common StockSEC:0000905148-26-001781:0
24,367 shares0Common StockSEC:0000905148-26-001782:0
24,367 shares0Common StockSEC:0000905148-26-001784:0
24,367 shares0Common StockSEC:0000905148-26-001785:0
24,367 shares0Common StockSEC:0000905148-26-001788:0
25 of 146 declarations
About Opus Genetics, Inc.
Opus Genetics, Inc. is a company focused on developing gene therapies for rare genetic diseases. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
